Orexigen Therapeutics
From Wikipedia, the free encyclopedia
Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is publicly listed on the NASDAQ exchange under the stock symbol OREX.[1]
| |
| Type | Public |
|---|---|
| Nasdaq: OREX | |
| Founded | 2002 |
| Founder | Eckard Weber |
| Headquarters | La Jolla, California, U.S. |
| Website | orexigen |
The company has a single product, Contrave, approved for use in the United States in 2014.[2][3] Contrave was designed not only to curb hunger but also reduce cravings.[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.[2][unreliable source?]
Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.[4][5]
